Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
RM Lyons, TM Cosgriff, SS Modi, RH Gersh… - Journal of clinical …, 2009 - ascopubs.org
Purpose Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a
dosing schedule of 75 mg/m2/d subcutaneously for 7 days every 4 weeks. The initial phase …
dosing schedule of 75 mg/m2/d subcutaneously for 7 days every 4 weeks. The initial phase …
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes
DP Steensma, RM Stone - Hematology/Oncology Clinics, 2010 - hemonc.theclinics.com
Background Azacitidine and decitabine are both potent inhibitors of DNA
methyltransferases, a family of enzymes that have been highly conserved throughout …
methyltransferases, a family of enzymes that have been highly conserved throughout …
"Not only presidential candidates from Illinois" Haematology news from ASCO 2008
W Willenbacher - memo-Magazine of European Medical Oncology, 2008 - Springer
At the haematological sessions of ASCO 2008 major progress was reported with regard to
multiple aspects of haematologic neoplasia. Highlights included the emerging role of JAK2 …
multiple aspects of haematologic neoplasia. Highlights included the emerging role of JAK2 …